Primary Therapeutic Uses of Megalia

Megalia is used in situations involving certain distressing symptoms related to significant, unexplained weight loss, such as anorexia and cachexia. It helps address symptoms that interfere with daily functioning by supporting patients in contexts involving systemic imbalance.

Its use is considered relevant for conditions presenting with symptoms of anorexia, cachexia, or unexplained significant weight loss in patients with specific diagnoses. The medication is commonly used across conditions presenting with acute episodes of weight-related distress. This use is applied across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden during periods of heightened symptoms.

This supportive function is relevant in clinical contexts. This role is relevant in contexts involving heightened systemic burden, and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Supports patients during periods of appetite changes

Megalia (Megestrol acetate) eligibility is strictly defined by regulatory authorities based on population characteristics and pre-existing conditions.

Eligibility Scope

Category	Regulatory Rule
Populations Allowed	Adults with anorexia, cachexia, or unexplained, significant weight loss, primarily associated with Acquired Immunodeficiency Syndrome (AIDS), or palliative treatment for advanced carcinoma.
Contraindicated Groups	Known or suspected pregnancy and patients with a history of hypersensitivity to megestrol acetate or any formulation component.
Age-Related Rules	Safety and effectiveness in the pediatric population (children) have not been established. Use in older adults requires caution, reflecting the greater frequency of decreased organ function.
Conditional Use	Use with caution in patients with a history of thromboembolic disease (e.g., blood clots) or diabetes mellitus.

Pregnancy and Lactation Status

• Pregnancy Status: Use is contraindicated. Women of childbearing potential are required to use effective contraception during treatment.
• Lactation Status: Nursing mothers must discontinue breastfeeding if the medicine is required, due to potential adverse effects on the newborn.

Comorbidity Restrictions

Therapy for weight loss should only be instituted after treatable causes (e.g., infections, malignancies, endocrine disease) are sought and addressed. The medicine is not intended for prophylactic use to avoid weight loss, as stated in official labeling.

---

Connection to the overall eligibility profile: Official regulatory documents classify specific groups as contraindicated (e.g., pregnant patients) or requiring caution (e.g., those with diabetes or a history of blood clots). These restrictions, along with the classification of use not established in children, strictly govern the eligible population for Megalia.

Interactions with other medicines and products

This section outlines the clinically significant interaction patterns of Megestrol acetate (Megalia) as formally documented in government regulatory prescribing information.

Documented Interaction Patterns

The medicine's interaction profile includes pharmacokinetic and pharmacodynamic effects with certain co-administered medicinal products, which require monitoring as outlined in official labeling.

Category	Officially Documented Interaction	Constraint/Requirement
Pharmacokinetic	Co-administration results in a significant decrease in Indinavir plasma exposure.	Dose adjustment of Indinavir may be required.
Pharmacodynamic	May increase International Normalized Ratio (INR) when combined with Warfarin.	Requires close and frequent monitoring of INR.
Pharmacodynamic	May reduce the therapeutic efficacy of antidiabetic agents (e.g., insulin).	Requires monitoring of blood glucose levels.

Population-Specific Interaction Notes

Official labeling indicates that caution is required in elderly patients and individuals with impaired renal function. This consideration is due to the potential for the drug's clearance to be reduced in these populations, which may lead to an increased risk of toxic reactions from Megestrol acetate itself.

There are no officially documented timing-based separation rules or explicit drug-drug contraindicated combinations listed in the primary regulatory interaction sections.

Megalia functions as a highly selective covalent inhibitor targeting the Guanosine Triphosphatase (GTPase) K-Ras G12C mutant protein. This molecular interaction occurs primarily in cells overexpressing the mutant protein, facilitating selective accumulation at the target site.

Upon binding, Megalia locks the K-Ras G12C protein into an inactive Guanosine Diphosphate (GDP)-bound state, preventing the essential nucleotide exchange to Guanosine Triphosphate (GTP) required for activation. This interruption effectively blocks the activation of the downstream Raf/MEK/ERK Mitogen-Activated Protein Kinase (MAPK) signaling cascade.

The intracellular consequence is a profound reduction in phosphorylated Extracellular signal-regulated kinase (pERK) levels in the cytoplasm and nucleus. This disruption modulates the activity of key transcription factors typically promoted by the MAPK pathway, leading to a system-level decrease in cell cycle progression signals and subsequent suppression of cell proliferation and survival mechanisms.

Megalia (megestrol acetate) is approved exclusively for oral administration, utilizing either tablets or a liquid oral suspension. The standard use is highly dependent on the approved indication, with specific dosage and frequency clearly defined by regulatory documents.

Administration Context	Daily Dose and Frequency	Route
Appetite Stimulation	625 mg or 800 mg once daily	Oral Suspension
Hormonal Uses	40 mg to 320 mg per day in divided doses	Oral Tablets

When using the oral suspension, the container must be shaken well before each use to ensure proper concentration of the active ingredient. A critical constraint in administration is the non-interchangeability of the two main suspension concentrations (e.g., 125 mg/mL vs. 40 mg/mL); these are not bioequivalent on a milligram-to-milligram basis, and the designated total daily doses must be followed precisely.

For specific populations, such as older adults, official administration rules require caution in dose selection, often advising initiation at the low end of the established dosing range. Furthermore, therapy for weight loss is intended to be instituted only after potentially treatable underlying causes have been sought and addressed. The overall use protocol also defines duration, such as requiring at least two months of continuous treatment before assessing efficacy for hormonal conditions. These rules define the standardized use protocol.

Research evidence / Overview of studies for Megalia

Evidence for Use in AIDS-Related Anorexia and Cachexia

Megalia was studied for the purpose of exploring the effect of the compound in adult patients with AIDS-related weight loss through short-term, randomized controlled trials (RCTs) and subsequent systematic reviews. These studies primarily compared the compound against a placebo. Researchers monitored changes in total body weight and patient-reported outcomes related to appetite status and food intake. Findings describe patterns observed where a difference in measured weight was reported between the study groups. However, research highlights that the measured weight change appeared to be largely composed of adipose (fat) tissue rather than lean body mass (muscle).

Evidence for Use in Cancer-Associated Wasting Syndrome

Megalia was studied for the purpose of exploring the effect of the compound in patients with cancer-associated wasting syndrome (cachexia) through double-blind, placebo-controlled RCTs and comprehensive systematic reviews. Studies monitored changes in total body weight and appetite status. Research has explored how body weight evolved, but evidence quality varies across studies, and some meta-analyses reported that findings were mixed regarding the consistency of overall weight change. Data show patterns related to the gained weight being characterized primarily as fat mass.

Research on Endometrial Atypical Hyperplasia

Megalia was evaluated for a separate hormonal application in patients with endometrial intraepithelial neoplasia (atypical hyperplasia). This evidence base is derived from smaller Phase II randomized controlled trials. Research examined outcomes linked to tissue regression by monitoring the rate of histologic response. Findings describe patterns observed in the studies related to the frequency of tissue regression over defined time intervals, typically 3 to 6 months.

What is Still Uncertain About Megalia Research

A common pattern observed across the main effectiveness trials is that follow-up durations were limited, typically 4 to 12 weeks. Therefore, long-term effects are not fully established regarding the durability of the observed weight changes. Research also provides limited insight into how the findings relate to lean body mass or muscle function, and data for certain patient groups remain insufficient, including specific populations defined by age.

Key Studies & References

1. Megestrol acetate in patients with AIDS and cachexia - Randomized Controlled Trial
2. Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis
3. Management of Endometrial Hyperplasia - RCOG Green-top Guideline No. 67

Common questions about Megalia (FAQ)

---

Q: Is Megalia the same type of medicine as [similar drug name]?

Megalia's active ingredient, megestrol acetate, is officially classified as a synthetic progestin (progestogen). This means it is a man-made substance designed to mimic the essential activity of the natural hormone progesterone. This pharmacological class designation, found in the official labeling, helps define how the medicine is generally described.

Q: Are there common or minor side effects I should know about?

Official product labeling documents adverse reactions by their incidence in clinical studies. Common effects are those reported in 1% to 10% of patients and may include gastrointestinal symptoms like nausea, diarrhea, and vomiting, as well as flatulence and headache. This information helps patients understand the documented safety profile.

Q: What happens if a dose of Megalia is missed?

Regulatory-sourced patient information often suggests taking the missed dose as soon as possible if remembered. However, if it is nearly time for the next scheduled dose, the missed dose may be skipped. The recommendation is to return to the regular dosing schedule, and official documentation does not advise doubling a dose.

Q: Is Megalia used for purposes other than [main use]?

The medicine is officially approved for two main purposes: hormonal modulation in the palliative treatment of advanced breast or endometrial cancer, and the treatment of anorexia, cachexia, or unexplained significant weight loss, such as that associated with Acquired Immunodeficiency Syndrome (AIDS). The use is defined by these specific, regulatorily approved indications.

Q: Can Megalia cause weight gain or weight loss?

Megalia is officially approved for treating conditions involving unwanted significant weight loss (cachexia), where its purpose is to help promote weight increase. Separately, weight gain is also listed in the official safety profile as a common adverse reaction, which means it occurred in 1% to 10% of patients in clinical studies.

Q: What should I do if I suspect a severe side effect from Megalia?

Official regulatory patient information advises contacting a health professional for guidance on any concerning symptoms. For signs of a serious adverse event, such as symptoms suggestive of a blood clot (e.g., sudden chest pain or difficulty breathing), seeking emergency medical assistance is described as necessary.

Q: How quickly should I expect Megalia to start working?

Official documents define how long treatment should continue before its effect is assessed. For some approved uses, regulatory guidance specifies that the medicine should be taken for at least two months of continuous use before efficacy is determined. The full effects are assessed based on this defined duration.

Q: Do food or drinks affect how Megalia works?

According to the official product information and administration guidelines, Megalia can be taken with or without food. Therefore, the timing of meals is generally not required to be adjusted relative to the medicine's administration.

Q: Are there any tests needed before starting Megalia?

Official precautions state that for the treatment of weight loss, therapy is intended to be instituted only after potentially treatable causes of the weight loss have been identified and addressed. This initial investigation by a health professional often requires laboratory testing and clinical evaluation before starting the medicine.

Q: Is it common to feel [non-specific minor symptom] when starting Megalia?

The official safety profile lists several effects as common (occurring in 1% to 10% of patients in studies), including nausea, diarrhea, and headache. These are effects often experienced when the body begins to adjust to a new medication. Any symptom that is bothersome or persistent can be documented for review with a health professional.

Q: How is Megalia different from a placebo in studies?

In clinical trials, Megalia is compared against a placebo (an inactive substance) to measure its effect. Studies report that Megalia is observed to produce a measurable difference in outcomes such as total body weight and appetite status. The medicine's known action involves selective binding to the K-Ras G12C protein, which is distinct from a placebo's lack of action.

Q: Are there specific instructions for stopping Megalia treatment?

Official safety notes state that the risk of adrenal insufficiency is a specific concern associated with the abrupt cessation of the medication. Therefore, official regulatory guidance suggests that discontinuation be managed under the supervision of a health professional.

Q: Can Megalia be used by people who are pregnant or breastfeeding?

Use is contraindicated in pregnancy due to the potential for harm to the fetus. Official guidelines also state that nursing mothers are required to discontinue breastfeeding if the medicine is necessary, due to the potential for adverse effects on the newborn. Women of childbearing potential are required to use effective contraception during treatment.

Q: What is the risk of an allergic reaction to Megalia?

Official regulatory documents list known or suspected hypersensitivity to the drug or any component as a contraindication, meaning the medicine should not be used in this situation. General allergic reactions, such as rash or hives, are also documented under adverse reactions in the official safety profile.

Q: Does Megalia interact with alcohol?

Patient information derived from regulatory sources often describes that the consumption of alcohol (in small amounts) does not appear to affect the safety or usefulness of Megalia. However, as alcohol can affect certain medical conditions, any use of alcohol can be discussed with a health professional.

Q: Is Megalia approved in other countries besides [country of reference]?

The active ingredient in Megalia (megestrol acetate) has approved indications and is marketed widely throughout the world for its labeled purposes. Approved indications are granted by the regulatory bodies in each territory and may vary slightly between countries.

Q: Do most patients tolerate Megalia well?

The official safety profile classifies documented side effects by frequency. Common effects are reported in 1% to 10% of patients in clinical studies, indicating that the majority of patients in these trials did not report these common adverse events. However, individual experiences with tolerability can vary.

Q: Is Megalia a new drug or has it been around for a while?

The active ingredient in Megalia, megestrol acetate, has been in use for a long time. The substance was first synthesized in 1959 and has been used for medical purposes, including for cancer treatment, since the early 1970s.

How to Store and Dispose of Megalia?

Labeled Storage Temperature Requirements	Store at Controlled Room Temperature, typically 25 C (77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F).
Handling Requirements	The oral suspension must not be refrigerated to prevent the active ingredient from crystallizing. Tablets and suspension must be protected from excessive heat (above 40 C).
Packaging-Related Storage Rules	Keep the medication in a tightly closed container to protect it from moisture.
Child-Protection Storage Requirements	The product must be stored strictly out of the sight and reach of children and pets in a safe location.
Disposal Instructions	Unused or expired Megalia must be disposed of according to local regulatory guidelines. Do not flush the medicine down the toilet or pour it down a drain unless specifically instructed to do so.

Official regulatory documents define the storage profile of Megalia by requiring adherence to Controlled Room Temperature and mandating the use of a tight container for environmental protection. Stability constraints are enforced through specific temperature rules, including the prohibition against refrigerating the liquid form. Disposal rules emphasize following local regulations and explicitly mandate child-safe storage.